patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_579849 | REC_0009001 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 26 | 5.2 | 62 | male | 1 | 25 | 5.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 42.3 | false | MSS | 2026-03-15T05:35:59.074783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733907 | REC_0009002 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 8.7 | 75 | female | 1 | 14 | 5.7 | 1 | osimertinib 80 mg daily | 24 | false | MSS | 2026-03-15T05:35:59.075026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228812 | REC_0009003 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 15.9 | 60 | female | 0 | 17 | 6.6 | 9 | entrectinib 600 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:59.075278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873753 | REC_0009004 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15 | 74 | female | 0 | 9 | 7.1 | 6 | alectinib 600 mg BID | 14.3 | false | MSI-H | 2026-03-15T05:35:59.075525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792091 | REC_0009005 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.2 | 56 | male | 0 | 23 | 4.4 | 6 | entrectinib 600 mg daily | 12.5 | false | MSS | 2026-03-15T05:35:59.075772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864863 | REC_0009006 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 17.2 | 68 | female | 1 | 32 | 6.5 | 5 | entrectinib 600 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:59.076020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327721 | REC_0009007 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12 | 58 | female | 1 | 17 | 6 | 7 | entrectinib 600 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:59.076336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338933 | REC_0009008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 13.5 | 51 | male | 0 | 16 | 5.2 | 4 | entrectinib 600 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:59.076600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748970 | REC_0009009 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 12.5 | 73 | female | 1 | 11 | 5.6 | 0 | osimertinib 80 mg daily | 31.9 | true | MSS | 2026-03-15T05:35:59.076858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626443 | REC_0009010 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 8.6 | 65 | male | 1 | 12 | 5.4 | 2 | osimertinib 80 mg daily | 19.7 | false | MSS | 2026-03-15T05:35:59.077233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406185 | REC_0009011 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 7.8 | 79 | female | 2 | 25 | 4.7 | 5 | alectinib 600 mg BID | 6.3 | false | MSS | 2026-03-15T05:35:59.077500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547990 | REC_0009012 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.8 | 65 | female | 1 | 18 | 6.2 | 7 | sotorasib 960 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:59.077743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277103 | REC_0009013 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 16.8 | 83 | female | 0 | 17 | 7.4 | 6 | pembrolizumab 200 mg q3w | 4.8 | true | MSS | 2026-03-15T05:35:59.077977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416895 | REC_0009014 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 9.7 | 68 | female | 1 | 18 | 9.8 | 1 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:59.078204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539810 | REC_0009015 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 8.3 | 55 | female | 0 | 35 | 5.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.2 | false | MSS | 2026-03-15T05:35:59.078448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526869 | REC_0009016 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.7 | 77 | female | 2 | 13 | 2.8 | 2 | osimertinib 80 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:35:59.078690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838171 | REC_0009017 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.1 | 86 | female | 0 | 74 | 7.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.3 | false | MSS | 2026-03-15T05:35:59.078931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848628 | REC_0009018 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.1 | 72 | female | 2 | 15 | 5.4 | 2 | alectinib 600 mg BID | 29 | true | MSI-H | 2026-03-15T05:35:59.079180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791099 | REC_0009019 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.4 | 54 | female | 0 | 37 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.6 | true | MSS | 2026-03-15T05:35:59.079429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250749 | REC_0009020 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 13.9 | 90 | female | 1 | 20 | 4.3 | 6 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:59.079673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112629 | REC_0009021 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13.9 | 71 | male | 2 | 16 | 3.8 | 2 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:59.079918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824410 | REC_0009022 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 8.9 | 65 | female | 0 | 13 | 4.9 | 2 | sotorasib 960 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:59.080306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791931 | REC_0009023 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 6.1 | 90 | male | 2 | 51 | 8.4 | 8 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:59.080681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995217 | REC_0009024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10 | 69 | female | 0 | 14 | 6.1 | 0 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.080947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468279 | REC_0009025 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 10.5 | 78 | female | 1 | 12 | 3.5 | 4 | pembrolizumab 200 mg q3w | 16.4 | true | MSI-H | 2026-03-15T05:35:59.081204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260009 | REC_0009026 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.7 | 65 | female | 1 | 16 | 6.4 | 4 | alectinib 600 mg BID | 13.7 | false | MSI-H | 2026-03-15T05:35:59.081465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519846 | REC_0009027 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 7.2 | 58 | female | 0 | 10 | 6.1 | 2 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.081717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751194 | REC_0009028 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 3.9 | 66 | female | 1 | 38 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.8 | false | MSS | 2026-03-15T05:35:59.081961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585356 | REC_0009029 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15.2 | 75 | female | 2 | 21 | 5.1 | 9 | alectinib 600 mg BID | 10.5 | true | MSI-H | 2026-03-15T05:35:59.082211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197150 | REC_0009030 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 13 | 69 | female | 1 | 10 | 5.2 | 3 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:59.082455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982894 | REC_0009031 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.7 | 76 | male | 3 | 56 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.6 | true | MSS | 2026-03-15T05:35:59.082698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127830 | REC_0009032 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 5.5 | 66 | female | 0 | 35 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.1 | false | MSS | 2026-03-15T05:35:59.082941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347705 | REC_0009033 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.8 | 47 | female | 0 | 13 | 4.6 | 6 | entrectinib 600 mg daily | 5.4 | true | MSS | 2026-03-15T05:35:59.083184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763212 | REC_0009034 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 8.2 | 60 | female | 1 | 19 | 4.3 | 6 | sotorasib 960 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:59.083422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265529 | REC_0009035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 8 | 65 | female | 0 | 17 | 6.2 | 9 | entrectinib 600 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.083660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318869 | REC_0009036 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 7 | 61 | female | 0 | 14 | 4.8 | 2 | osimertinib 80 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.083995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500493 | REC_0009037 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 10.2 | 66 | female | 1 | 12 | 3.9 | 2 | osimertinib 80 mg daily | 16.7 | false | MSS | 2026-03-15T05:35:59.084291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366615 | REC_0009038 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.7 | 71 | female | 2 | 51 | 4.7 | 5 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:35:59.084540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245650 | REC_0009039 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.6 | 55 | female | 1 | 11 | 6.2 | 6 | sotorasib 960 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:59.084797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128677 | REC_0009040 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 7.8 | 74 | female | 1 | 3 | 4.2 | 6 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.085033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774393 | REC_0009041 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14.1 | 63 | female | 1 | 25 | 6 | 1 | sotorasib 960 mg daily | 17.2 | true | MSI-H | 2026-03-15T05:35:59.085286+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791184 | REC_0009042 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 9.9 | 68 | male | 1 | 20 | 6.2 | 2 | entrectinib 600 mg daily | 21.2 | false | MSS | 2026-03-15T05:35:59.085527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466095 | REC_0009043 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 8.1 | 65 | male | 1 | 16 | 5.2 | 1 | sotorasib 960 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:59.085768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254083 | REC_0009044 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 10.2 | 68 | female | 1 | 26 | 4.9 | 0 | osimertinib 80 mg daily | 31.7 | false | MSI-H | 2026-03-15T05:35:59.086015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161636 | REC_0009045 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 12 | 63 | female | 1 | 15 | 5.8 | 6 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:59.086267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883160 | REC_0009046 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.6 | 57 | male | 0 | 8 | 6.1 | 4 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:59.086515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347178 | REC_0009047 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 1.6 | 79 | male | 1 | 54 | 7.2 | 8 | pembrolizumab 200 mg q3w | 8 | true | MSS | 2026-03-15T05:35:59.086755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600642 | REC_0009048 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.5 | 69 | female | 0 | 52 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.3 | false | MSS | 2026-03-15T05:35:59.086993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334261 | REC_0009049 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 8 | 54 | male | 0 | 16 | 7.3 | 1 | osimertinib 80 mg daily | 11 | false | MSS | 2026-03-15T05:35:59.087334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801002 | REC_0009050 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 5.8 | 70 | female | 2 | 9 | 6.2 | 6 | osimertinib 80 mg daily | 10.4 | false | MSS | 2026-03-15T05:35:59.087573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622652 | REC_0009051 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 8.8 | 61 | female | 0 | 14 | 4.5 | 3 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.087813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941161 | REC_0009052 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 12.4 | 63 | female | 0 | 13 | 4.8 | 2 | osimertinib 80 mg daily | 22.6 | true | MSI-H | 2026-03-15T05:35:59.088051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826887 | REC_0009053 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 12.2 | 72 | male | 0 | 9 | 4 | 1 | entrectinib 600 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:59.088337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711025 | REC_0009054 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 18 | 10.4 | 70 | female | 1 | 25 | 4 | 7 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:35:59.088573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463964 | REC_0009055 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 16 | 44 | male | 0 | 15 | 5 | 0 | sotorasib 960 mg daily | 25.7 | true | MSI-H | 2026-03-15T05:35:59.088813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830504 | REC_0009056 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 4.7 | 63 | male | 1 | 25 | 5.8 | 0 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:35:59.089046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363222 | REC_0009057 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 8.4 | 68 | female | 0 | 2 | 4.9 | 2 | alectinib 600 mg BID | 11.3 | true | MSS | 2026-03-15T05:35:59.089282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702863 | REC_0009058 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.4 | 55 | female | 0 | 15 | 5.2 | 1 | pembrolizumab 200 mg q3w | 20.5 | false | MSI-H | 2026-03-15T05:35:59.089521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152193 | REC_0009059 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4 | 68 | male | 0 | 23 | 3.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.089761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474093 | REC_0009060 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 13.1 | 75 | female | 1 | 16 | 4.4 | 2 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:59.090007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324010 | REC_0009061 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 16 | 67 | female | 1 | 17 | 5.5 | 0 | alectinib 600 mg BID | 59.6 | true | MSS | 2026-03-15T05:35:59.090241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955416 | REC_0009062 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 10.9 | 58 | male | 0 | 13 | 4.6 | 2 | sotorasib 960 mg daily | 8.8 | true | MSS | 2026-03-15T05:35:59.090554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528468 | REC_0009063 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 8 | 61 | female | 1 | 26 | 5 | 6 | entrectinib 600 mg daily | 5.3 | true | MSS | 2026-03-15T05:35:59.090803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790601 | REC_0009064 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.7 | 62 | female | 1 | 20 | 6.4 | 8 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:59.091041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765747 | REC_0009065 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.7 | 85 | male | 0 | 42 | 6.9 | 1 | pembrolizumab 200 mg q3w | 22.9 | false | MSS | 2026-03-15T05:35:59.091276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487228 | REC_0009066 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 5.9 | 72 | female | 2 | 63 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:35:59.091512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539570 | REC_0009067 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 6.7 | 68 | male | 1 | 5 | 4.9 | 1 | osimertinib 80 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:59.091749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335631 | REC_0009068 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.1 | 64 | female | 0 | 46 | 5.8 | 10 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:59.091983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545428 | REC_0009069 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 15.1 | 71 | female | 1 | 22 | 2 | 4 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:35:59.092290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990491 | REC_0009070 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 6 | 80 | male | 2 | 17 | 6 | 6 | pembrolizumab 200 mg q3w | 12 | true | MSS | 2026-03-15T05:35:59.092528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215257 | REC_0009071 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.9 | 66 | female | 0 | 18 | 6.2 | 2 | osimertinib 80 mg daily | 5.1 | false | MSI-H | 2026-03-15T05:35:59.092767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357635 | REC_0009072 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.4 | 60 | female | 1 | 43 | 5.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 5.9 | true | MSS | 2026-03-15T05:35:59.093000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311056 | REC_0009073 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9 | 67 | female | 0 | 9 | 4.2 | 6 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.093230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431461 | REC_0009074 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 21.2 | 64 | male | 0 | 12 | 5.4 | 1 | osimertinib 80 mg daily | 37 | false | MSS | 2026-03-15T05:35:59.093467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259368 | REC_0009075 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.6 | 63 | male | 0 | 15 | 6.6 | 4 | alectinib 600 mg BID | 5.1 | false | MSS | 2026-03-15T05:35:59.093772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456627 | REC_0009076 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 15.6 | 76 | female | 2 | 3 | 6.1 | 3 | osimertinib 80 mg daily | 23.4 | false | MSI-H | 2026-03-15T05:35:59.094008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593193 | REC_0009077 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.6 | 74 | male | 1 | 40 | 5.7 | 2 | pembrolizumab 200 mg q3w | 29.3 | false | MSS | 2026-03-15T05:35:59.094244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145268 | REC_0009078 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 7.1 | 58 | male | 0 | 4 | 4.2 | 6 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:35:59.094481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148588 | REC_0009079 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 12.8 | 63 | male | 1 | 19 | 8.4 | 6 | entrectinib 600 mg daily | 6.3 | true | MSI-H | 2026-03-15T05:35:59.094720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772481 | REC_0009080 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.7 | 68 | female | 0 | 16 | 4.5 | 5 | sotorasib 960 mg daily | 19 | true | MSI-H | 2026-03-15T05:35:59.094956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135248 | REC_0009081 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 17.5 | 66 | male | 0 | 13 | 6.3 | 2 | osimertinib 80 mg daily | 20.4 | true | MSI-H | 2026-03-15T05:35:59.095197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143392 | REC_0009082 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 7.8 | 73 | female | 2 | 14 | 7 | 3 | alectinib 600 mg BID | 11.7 | false | MSS | 2026-03-15T05:35:59.095436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816502 | REC_0009083 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.2 | 76 | female | 1 | 18 | 6.3 | 7 | osimertinib 80 mg daily | 7.3 | false | MSS | 2026-03-15T05:35:59.095677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357069 | REC_0009084 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 6.7 | 74 | female | 2 | 9 | 6.4 | 6 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:35:59.095905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_820937 | REC_0009085 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13.2 | 64 | female | 0 | 15 | 6.8 | 8 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:59.096259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589568 | REC_0009086 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.9 | 64 | female | 0 | 2 | 7.1 | 6 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:59.096514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368378 | REC_0009087 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 7.8 | 69 | female | 1 | 14 | 4.8 | 2 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.096754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260995 | REC_0009088 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 5.1 | 57 | female | 0 | 17 | 5.6 | 5 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.097098+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349563 | REC_0009089 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 10.3 | 74 | male | 2 | 9 | 4.6 | 5 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:59.097360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185374 | REC_0009090 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 10.4 | 72 | male | 1 | 19 | 6.9 | 1 | alectinib 600 mg BID | 29.1 | true | MSI-H | 2026-03-15T05:35:59.097616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113270 | REC_0009091 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 15.2 | 58 | male | 0 | 18 | 4.3 | 8 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:35:59.097860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_533342 | REC_0009092 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 7.8 | 55 | male | 0 | 22 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.1 | false | MSS | 2026-03-15T05:35:59.098095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117402 | REC_0009093 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 6.1 | 67 | female | 1 | 6 | 3.9 | 6 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:59.098326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936617 | REC_0009094 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.9 | 70 | female | 1 | 29 | 5.3 | 1 | alectinib 600 mg BID | 12 | false | MSI-H | 2026-03-15T05:35:59.098558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356759 | REC_0009095 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 12.2 | 58 | female | 1 | 16 | 6.1 | 5 | entrectinib 600 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:59.098795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210099 | REC_0009096 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.2 | 63 | male | 1 | 49 | 6.4 | 5 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:59.099029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744779 | REC_0009097 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.8 | 57 | female | 0 | 37 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.7 | false | MSS | 2026-03-15T05:35:59.099263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846493 | REC_0009098 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8 | 76 | female | 3 | 22 | 4 | 5 | osimertinib 80 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:59.099495+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575084 | REC_0009099 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 13.4 | 73 | female | 1 | 18 | 4.5 | 2 | alectinib 600 mg BID | 19.4 | false | MSI-H | 2026-03-15T05:35:59.099724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406928 | REC_0009100 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.6 | 60 | female | 1 | 30 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.6 | false | MSS | 2026-03-15T05:35:59.099956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.